Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is an open, blank controlled clinical trial to evaluate the efficacy and safety of SA58 nasal spray in the prevention COVID-19 infection among health care workers at high risk of SARS-CoV-2 infection.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sinovac Life Sciences Co., Ltd.

Criteria

Inclusion Criteria:

• Medical staff working in the designated COVID-19 hospitals and Fangcang shelter hospitals (alternate care sites) of COVID-19 cases in Hohhot;

• Subjects were 18 years of age and older and in good health;

• Subjects volunteered to use COVID-19 neutralizing antibody nasal spray.

Exclusion Criteria:

• Previous history of severe allergies or sensitivity to inhaled allergens;

• Women who were pregnant or breastfeeding;

• Subjects were unable to cooperate with nasal spray inhalation;

• Other conditions for which medication was not appropriate.